A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix
- 1 January 1990
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 27 (1) , 52-54
- https://doi.org/10.1007/bf00689276
Abstract
A total of 44 women received a combination of ifosfamide (1.5 g/m2 daily x5) and cisplatin (50 mg/m2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38%) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic death. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.Keywords
This publication has 7 references indexed in Scilit:
- Phase II Studies of Bleomycin, Ifosfamide and Cis-Platinum in Advanced and Recurrent Cervical CarcinomaActa Oncologica, 1988
- A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervixCancer Chemotherapy and Pharmacology, 1986
- PROTECTIVE EFFECT OF SODIUM-2-MERCAPTOETHANESULFONATE ON THE GASTROINTESTINAL TOXICITY AND LETHALITY OF CIS-DIAMMINEDICHLOROPLATINUM1986
- PHASE-II STUDY OF IFOSFAMIDE IN CERVICAL-CANCER1986
- ENCEPHALOPATHY ASSOCIATED WITH IFOSPHAMIDE/MESNA THERAPYThe Lancet, 1985
- Cervical carcinoma: A drug-responsive tumor—experience with combined cisplatin, vinblastine, and bleomycin therapyGynecologic Oncology, 1983
- Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase ii study of the gynecologic oncology groupCancer, 1981